Author: Angeline Leishman|| Date Published: December 30, 2021
Merck’s life science business has been awarded a three-year, $136.7 million contract to stand up a factory for a critical material needed to manufacture rapid COVID-19 point-of-care tests.
MilliporeSigma said Thursday it will use the funds to establish a lateral flow membrane production facility in Sheboygan, Wisconsin, to support domestic production and supply efforts for the government’s pandemic preparedness initiative.
The business supplies its Hi-Flow Plus nitrocellulose membrane to manufacturers of medical test kits intended to diagnose infectious diseases such as COVID-19, malaria and HIV.
The Department of Veterans Affairs has issued a presolicitation for the Veterans Health Administration’s Biomedical Engineering Technical Professional Support Services, or…
Trident Solutions has acquired space electronics developer Ibeos, expanding its capabilities in on-orbit computing and power systems used in government…